Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

140.71 +0.65 (+0.46%)
Delayed Quote Updated: 3:26 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Via ACCESSWIRE
News headline image
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Via ACCESSWIRE
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Via ACCESSWIRE
News headline image
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Via ACCESSWIRE
News headline image
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines ↗
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
News headline image
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Via ACCESSWIRE
News headline image
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
Via ACCESSWIRE
News headline image
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Via ACCESSWIRE
News headline image
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
News headline image
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Via ACCESSWIRE
News headline image
3 Growth Stocks No One Is Watching (But They Should Be) ↗
While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential. 
Via InvestorPlace
News headline image
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 ↗
Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
Via Investor's Business Daily
Topics Stocks
News headline image
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Via ACCESSWIRE
News headline image
The 3 Best Biotech Stocks to Buy in June 2024 ↗
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
Via InvestorPlace
News headline image
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Via ACCESSWIRE
News headline image
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Via ACCESSWIRE
News headline image
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
News headline image
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Via ACCESSWIRE
News headline image
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.